Korsana Biosciences, Inc. (KRSA) stock
KRSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30493% above fair value
$32.50−0.18 (-0.55%)
Close on Nov 17, 2026Market cap $152.14MP/E –Yield –
Earnings
Korsana Biosciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$3.19
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Korsana Biosciences's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026before the open | – | – | -$3.19 | Release |
| Q2 FY2026ended Jun 30, 2026 | Sep 11, 2026after the close | – | – | – | Release |
| Q1 FY2023ended Mar 31, 2023 | May 12, 2023after the close | – | – | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 22, 2023after the close | – | – | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 9, 2022after the close | – | – | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 4, 2022after the close | – | – | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 24, 2022after the close | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 9, 2021after the close | – | – | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 29, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 27, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Jan 13, 2021before the open | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Jul 9, 2020after the close | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | Apr 14, 2020after the close | – | – | – | Filing |
| Q3 FY2019ended Sep 30, 2019 | Oct 30, 2019before the open | – | – | – | Filing |
| Q2 FY2019ended Jun 30, 2019 | Aug 12, 2019before the open | – | – | – | Filing |
| Q1 FY2019ended Mar 31, 2019 | May 13, 2019before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Korsana Biosciences has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Korsana Biosciences puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Korsana Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously AnnouncedResults
- Results
- Results
- Update
- Update
- Update
- Update
- Update
- Update
- Update
- Update
- Update
- Update
- Update
See a number that looks wrong?